KRAS and cancer: established that BEZ235 arrested proliferation in all 21 cancer cell lines usedin their study, independent of PI3K pathway mutation status [39], and that cell lines with aBRAF or KRAS mutation or EGFRamplification were slightly less sensitive to BEZ235 compared to the other cell lines[39].